The top U.S. pharmacy in 2024 by market share based on prescription drug revenue was CVS Health Corporation, followed by Walgreens Boots Alliance. CVS Health held over 25 percent of the prescription drug market revenue at that time. A significant increase in market share was reported for Cigna achieved through the acquisition of pharmacy benefit manager Express Scripts in August 2018. Before that, Cigna was mainly active in the insurance business and related products and services. CVS pharmaciesThe CVS Health Corporation is a health service company with locations all over the United States, Puerto Rico and Brazil. CVS Health comprises pharmacies, clinics and retail locations. According to recent estimates the number of CVS pharmacies has increased dramatically since 2005, however, with a downward tendency since 2021.Pharmaceutical and pharmacy marketThe U.S. has the largest single share of global pharmaceutical market revenues. The total number of prescriptions dispensed in the U.S. has increased in the last years, reaching around 6.7 billion medical prescriptions in 2022. Prescription drug expenditures have been increasing in value, while the share related to total U.S. health expenditures has remained stable in recent years. On the other hand, the pharmacy market recently saw some significant changes, especially with the growing impact of online pharmacies (mail-order pharmacies) worldwide.

This dataset provides data for new prescription drugs introduced to market in California with a Wholesale Acquisition Cost (WAC) that exceeds the Medicare Part D specialty drug cost threshold. Prescription drug manufacturers submit information to HCAI within a specified time period after a drug is introduced to market. Key data elements include the National Drug Code (NDC) administered by the FDA, a narrative description of marketing and pricing plans, and WAC, among other information. Manufacturers may withhold information that is not in the public domain. Note that prescription drug manufacturers are able to submit new drug reports for a prior quarter at any time. Therefore, the data set may include additional new drug report(s) from previous quarter(s).

There are two types of New Drug data sets: Monthly and Annual. The Monthly data sets include the data in completed reports submitted by manufacturers for calendar year 2025, as of November 7, 2025. The Annual data sets include data in completed reports submitted by manufacturers for the specified year. The data sets may include reports that do not meet the specified minimum thresholds for reporting.

The program regulations are available here: https://hcai.ca.gov/wp-content/uploads/2024/03/CTRx-Regulations-Text.pdf

The data format and file specifications are available here: https://hcai.ca.gov/wp-content/uploads/2024/03/Format-and-File-Specifications-version-2.0-ada.pdf

DATA NOTES: Due to recent changes in Excel capabilities, it is not recommended that you save these files to .csv format. If you do, when importing back into Excel the leading zeros in the NDC number column will be dropped. If you need to save it into a different format other than .xlsx it must be .txt

Submitted reports that are still under review by HCAI are not included in these files.

DATA UPDATES: Drug manufacturers may submit New Drug reports to HCAI for prescription drugs which were not initially reported when they were introduced to market. CTRx staff update the posted datasets monthly for current year data and as needed for previous years. Please check the 'Data last updated' date on each dataset page to ensure you are viewing the most current data.

In 2024, the top pharmacy benefit managers included Cigna, CVS Health, and OptumRx, to name the most important. Cigna had the largest share of the pharmacy benefit manager market in that year, holding ** percent of the market. Pharmacy benefit managers are an influential part of the prescription drug supply chain in the United States. Pharmacy benefit managers Pharmacy benefit managers are responsible for the operation and distribution of pharmaceuticals to patients and pharmacies. They are also responsible for the negotiation of rebates and processing of insurance claims from patients and pharmacies. Among pharmaceutical distributors in the U.S., chain stores distributed the largest value of pharmaceuticals recently. However, data suggests that pharmacy benefit managers have the highest gross profit among all actors in the U.S. drugs supply chain. Generic drugs Lately, the growth of the generic prescriptions volume in the U.S. market has remained fairly stable, with growth in all years. With stable growth in generics, the number of brand name medicines that were excluded from pharmacy benefit manager formularies recently had been on the rise. Generic drugs are useful to the consumer in that, in many cases, they provide a cheaper alternative to brand name drugs.

This statistic depicts a projection for the total prescription drug revenue worldwide from 2023 to 2030. In 2025, the industry is expected to generate *** trillion U.S. dollars in prescription drug revenue worldwide. Revenues are projected to exceed *** trillion U.S. dollars by 2030. There is an increasing growth, especially, in sales of so-called orphan drugs for the treatment of rare diseases.

The mail-order pharmacy market is booming, projected to reach $50.39 billion in 2025, with a CAGR of 15.8%. Driven by telehealth, chronic disease management, and online convenience, this report analyzes market trends, key players (CVS, Express Scripts, etc.), and regional growth in North America, Europe, and Asia.

Digital Prescription Market Outlook

According to our latest research, the global digital prescription market size reached USD 8.4 billion in 2024, demonstrating robust momentum as healthcare systems worldwide accelerate digital transformation. The market is projected to grow at a CAGR of 23.1% from 2025 to 2033, reaching an estimated USD 65.1 billion by 2033. This remarkable growth is primarily driven by the increasing adoption of electronic health records (EHRs), the need to reduce medication errors, and the growing demand for integrated healthcare solutions. The digital prescription market is witnessing a paradigm shift as healthcare providers and stakeholders embrace technology to improve patient outcomes and streamline prescription management processes.

A key growth factor propelling the digital prescription market is the global push towards healthcare digitization, spurred by government mandates and incentives. Several countries, particularly in North America and Europe, have implemented stringent regulations requiring the use of electronic prescribing systems to combat prescription fraud and enhance patient safety. These policies have prompted hospitals, clinics, and pharmacies to invest heavily in digital prescription solutions, leading to widespread adoption. Furthermore, the integration of digital prescription platforms with EHRs and pharmacy management systems has facilitated seamless data sharing, reducing administrative burden and improving workflow efficiency. As a result, healthcare providers are increasingly leveraging these technologies to deliver safer and more coordinated care.

Another significant driver is the rising prevalence of chronic diseases and the subsequent increase in prescription medication volumes. With aging populations and a surge in conditions such as diabetes, cardiovascular diseases, and respiratory disorders, healthcare systems are under pressure to manage large-scale prescription processes efficiently. Digital prescription platforms offer real-time decision support, automated drug interaction checks, and streamlined communication between physicians and pharmacists. These features not only minimize the risk of medication errors but also enhance patient adherence to prescribed treatment regimens. As healthcare providers prioritize patient-centric care, the demand for advanced digital prescription solutions is expected to escalate further.

The COVID-19 pandemic has played a pivotal role in accelerating the adoption of digital prescription solutions. Lockdowns, social distancing measures, and a surge in telemedicine consultations have underscored the need for contactless, remote prescription management. Digital prescription platforms have enabled healthcare professionals to issue, modify, and monitor prescriptions electronically, ensuring continuity of care while minimizing infection risks. The pandemic has also heightened patient awareness regarding the benefits of digital health tools, leading to a sustained increase in demand even in the post-pandemic era. As telehealth becomes an integral part of healthcare delivery, digital prescription systems are poised to become indispensable components of modern healthcare infrastructure.

E-Prescribing, a cornerstone of digital prescription solutions, is revolutionizing the way prescriptions are managed and dispensed. By enabling healthcare providers to send prescriptions electronically to pharmacies, E-Prescribing reduces the risk of errors associated with handwritten prescriptions and enhances the efficiency of the prescription process. This technology not only streamlines the workflow for healthcare professionals but also improves patient safety by providing real-time access to a patient's medication history and potential drug interactions. As the healthcare industry continues to embrace digital transformation, E-Prescribing is becoming an integral part of modern healthcare systems, offering a seamless and secure method for managing prescriptions and fostering better communication between providers and pharmacies. The widespread adoption of E-Prescribing is expected to drive significant improvements in medication adherence and patient outcomes, further solidifying its role in the future of healthcare delivery.

From a regional perspective, North America remains the dominant market for digital prescription solutions, accounting for the largest reve

In 2024, the Prescription Delivery Service Market was valued at $218.9 Mn, and it is projected to reach $362.7 Mn by 2030, due to increase in aging population.

The global Prescription Drugs Market size was estimated at USD 1.16 trillion in 2024 and is anticipated to grow at a CAGR of 6.94% from 2025 to 2034.

Prescription Delivery Services Market size is set to expand from $ 165.86 Million in 2024 to $ 320.22 Million by 2034,CAGR of around 6.8% from 2025 to 2034.

Between 2001 and 2023, the market value of prescription drugs in Italy experienced an overall decreasing trend. In fact, it amounted to more than ** billion euros in 2001, while by 2023 this figure shrank to almost **** billion euros. In 2020 was recorded the lowest value registered over the period, with **** billion euros. This figure shows the market value of prescription drugs in Italy from 2001 to 2023 (in million euros).

Between 2014 and 2023, the sales volume of the pharmaceutical market in Italy experienced a contraction. This was true for both prescription and nonprescription drugs. In fact, while in 2014 **** billion of prescription drugs' packages and *** million of nonprescription drugs' packages were sold, by 2023 these figures decreased to **** billion and *** million, respectively. This figure shows the sales volume of the pharmaceutical market in Italy from 2014 to 2023, by type of product (in million packages).

Pharmacy Prescription Retrieval Robot Market Outlook

According to our latest research, the global Pharmacy Prescription Retrieval Robot market size in 2024 stands at USD 1.83 billion, with a robust compound annual growth rate (CAGR) of 12.7% expected through the forecast period. By 2033, the market is projected to reach an impressive USD 5.45 billion, driven by advancements in automation, rising demand for efficient pharmacy workflows, and the increasing prevalence of chronic diseases necessitating prescription medications. The growth trajectory is significantly influenced by the rising adoption of robotics in healthcare settings to streamline prescription management, reduce errors, and enhance patient safety.

One of the primary growth factors propelling the Pharmacy Prescription Retrieval Robot market is the urgent need for operational efficiency in pharmacy environments. Pharmacies are under increasing pressure to handle higher prescription volumes while minimizing human errors and ensuring rapid service. The integration of prescription retrieval robots automates the process of picking, verifying, and dispensing medications, which not only reduces labor costs but also significantly enhances the accuracy and speed of prescription fulfillment. This automation addresses both the challenges of workforce shortages and the demand for improved patient care, making it a strategic investment for healthcare providers globally. Additionally, the ongoing digital transformation in healthcare is accelerating the deployment of advanced robotics, further supporting market expansion.

Another significant driver is the rising prevalence of chronic diseases and an aging population, both of which contribute to increased prescription drug consumption. As the global population ages, the burden on healthcare systems intensifies, necessitating solutions that can efficiently manage high prescription volumes. Pharmacy prescription retrieval robots offer a scalable solution that can adapt to varying pharmacy sizes and prescription loads, making them particularly attractive for both large hospital pharmacies and smaller retail outlets. Furthermore, the integration of these robots with electronic health records (EHR) and pharmacy management systems enhances workflow automation, streamlines inventory management, and ensures regulatory compliance, all of which are critical in today’s healthcare landscape.

Technological advancements in robotics, artificial intelligence, and machine learning are also fueling the market’s growth. Modern pharmacy prescription retrieval robots are equipped with sophisticated sensors, vision systems, and AI-powered algorithms that enable precise medication identification, real-time tracking, and adaptive learning for continuous performance improvement. These innovations not only increase the reliability and efficiency of pharmacy operations but also reduce the risk of medication errors, a major concern in patient safety. The development of user-friendly interfaces and seamless integration with existing pharmacy systems further lowers the adoption barrier, encouraging more healthcare organizations to invest in robotic solutions.

Regionally, North America currently dominates the Pharmacy Prescription Retrieval Robot market, accounting for the largest share in 2024, followed by Europe and Asia Pacific. The strong presence of technologically advanced healthcare infrastructure, high healthcare spending, and early adoption of automation technologies in the United States and Canada are key contributors to this regional leadership. Europe is also witnessing significant growth due to stringent regulatory requirements for medication safety and increasing investments in healthcare automation. Meanwhile, the Asia Pacific region is emerging as a lucrative market, driven by rapid healthcare modernization, expanding pharmaceutical sectors, and growing awareness about the benefits of robotic automation in pharmacy management. These regional trends are expected to shape the competitive landscape and growth opportunities throughout the forecast period.

Product Type Analysis

The Pharmacy Prescription Retrieval Robot market is segmented by product type into Automated Dispensing Robots, Prescription Retrieval Robots, Medication Storage Robots, and Others. Automated Dispensing Robots represent a significant share of the market, as these systems are designed to handle hi

The Sweden Pharmaceutical Market Report Segments the Industry Into by ATC/Therapeutic Class (Cardiovascular System, Dermatological, Genito Urinary System and Sex Hormones, Anti-Infective for Systemic Use, Antineoplastic and Immunomodulating Agents, Musculoskeletal System, Nervous System, Respiratory System, and More), by Drug Type (Branded, Generic), and by Prescription Type (Prescription Drugs (Rx), Over the Counter (OTC) Drugs).

The global pharmaceutical e-commerce market is experiencing robust growth, driven by increasing internet penetration, the convenience of online ordering, and a rising preference for telehealth services. This market, estimated at $150 billion in 2025, is projected to grow at a compound annual growth rate (CAGR) of 15% from 2025 to 2033. This significant expansion is fueled by several key factors. Firstly, the COVID-19 pandemic accelerated the adoption of online pharmacies, highlighting the convenience and safety of accessing medications remotely. Secondly, the growing elderly population, coupled with a rise in chronic diseases, necessitates convenient access to prescription refills and over-the-counter medications. Thirdly, the entry of major players like Amazon and established pharmacy chains into the online space is fostering competition and innovation, leading to improved services and lower prices. Furthermore, advancements in technology, such as mobile applications and telehealth platforms, are streamlining the online prescription process and enhancing patient engagement. However, challenges remain. Regulatory hurdles in certain regions, concerns about data privacy and security, and the need for robust verification systems to prevent counterfeiting and fraud are significant restraints. The market is segmented by prescription medications, over-the-counter products, and by gender (male and female), reflecting diverse consumer needs and preferences. Geographical distribution reveals strong growth in North America and Europe, driven by established healthcare infrastructure and high internet penetration rates. Emerging markets in Asia-Pacific are also showing significant potential, fueled by rapid economic growth and increasing healthcare spending. Competitive landscape analysis indicates a mix of established pharmaceutical companies, online marketplaces, and specialized e-pharmacies vying for market share. The projected CAGR of 15% suggests that the pharmaceutical e-commerce sector is poised for considerable expansion in the coming years, presenting both significant opportunities and challenges for stakeholders.

Prescription Price Transparency Tools Market Outlook

According to our latest research, the global prescription price transparency tools market size reached USD 1.42 billion in 2024, with a robust compound annual growth rate (CAGR) of 16.7% projected from 2025 to 2033. By the end of 2033, the market is expected to attain a value of USD 5.08 billion, driven by increasing regulatory mandates, the rising demand for cost-effective healthcare, and the growing adoption of digital health solutions worldwide. The primary growth factor is the intensifying need among patients, providers, and payers for real-time access to prescription drug pricing information, which is transforming the healthcare ecosystem by enhancing transparency and empowering informed decision-making.

One of the most significant growth factors for the prescription price transparency tools market is the escalating healthcare expenditure and the persistent rise in out-of-pocket costs for prescription medications. Patients are increasingly burdened by high drug prices, leading to medication non-adherence and poor health outcomes. Transparency tools help address this challenge by providing real-time, accurate pricing information, enabling patients to compare medication costs across pharmacies, insurance plans, and discount programs. The integration of these tools within electronic health record (EHR) systems and pharmacy benefit management (PBM) platforms is further amplifying their adoption. As healthcare systems globally shift toward value-based care models, the demand for solutions that promote price transparency and cost containment is expected to accelerate, fueling market growth.

Another critical driver is the evolving regulatory landscape, particularly in developed markets such as the United States and Europe. Governments and regulatory authorities are implementing policies that mandate healthcare providers and insurers to disclose drug pricing information to patients at the point of care. For instance, the Centers for Medicare & Medicaid Services (CMS) in the US has introduced rules requiring the use of real-time benefit tools (RTBTs) to provide patients with personalized out-of-pocket cost information before prescriptions are filled. These regulations are compelling healthcare organizations to invest in advanced transparency solutions, thereby expanding the market. Additionally, the growing emphasis on digital health transformation and the proliferation of telemedicine are further supporting the widespread deployment of prescription price transparency tools.

Technological advancements are also playing a pivotal role in shaping the prescription price transparency tools market. The integration of artificial intelligence (AI), machine learning, and big data analytics into these platforms is enhancing their predictive capabilities and delivering more personalized, actionable insights to users. Cloud-based deployment models are gaining traction due to their scalability, flexibility, and ease of integration with existing healthcare IT infrastructure. Moreover, the increasing collaboration between technology vendors, healthcare providers, and payers is fostering innovation and accelerating the development of user-friendly, interoperable solutions. As the healthcare industry continues to embrace digitalization, the adoption of sophisticated prescription price transparency tools is expected to surge, driving sustained market expansion.

From a regional perspective, North America currently dominates the prescription price transparency tools market, accounting for the largest share in 2024, followed by Europe and Asia Pacific. The strong presence of key market players, supportive regulatory frameworks, and high healthcare expenditure contribute to the region's leadership. However, Asia Pacific is emerging as a lucrative market, propelled by rapid digital health adoption, rising healthcare awareness, and government initiatives aimed at improving medication affordability. Latin America and the Middle East & Africa are also witnessing increased adoption, albeit at a slower pace, due to growing investments in healthcare infrastructure and digital health technologies. As these regions continue to evolve, the global landscape of prescription price transparency tools is expected to become more diversified and competitive.

Component Analysis

The component segment of the prescription price transparency tools market is bifurcated i

The global pharmaceutical retail chain market is experiencing steady growth, projected to maintain a Compound Annual Growth Rate (CAGR) of 5% from 2025 to 2033. While the precise market size for 2025 isn't explicitly stated, considering a typical market size in this sector and applying a logical extrapolation based on a 5% CAGR from a hypothetical 2019 base, we can estimate the 2025 market size to be around $500 billion. This growth is fueled by several key factors. The aging global population and the concomitant rise in chronic diseases necessitate increased pharmaceutical consumption, driving demand. Moreover, the expanding middle class in emerging economies is increasing access to healthcare and pharmaceuticals, further boosting market expansion. Technological advancements, such as online pharmacies and telehealth services, are transforming the retail landscape, improving accessibility and convenience for consumers. Increased government initiatives to improve healthcare infrastructure in developing nations also contribute to the market's growth. However, several challenges temper this growth. Stringent regulatory environments and pricing pressures from governmental bodies and insurance companies can impact profitability. The rise of generic drugs also presents competitive challenges for branded pharmaceutical companies. Furthermore, concerns over prescription drug abuse and counterfeit medications pose significant hurdles to overcome. The market is segmented by various factors including geographical location, product type, and distribution channels. Key players like CVS Health, Walgreens Boots Alliance, and Albertsons dominate the market, particularly in developed economies. The competitive landscape is intensely dynamic with ongoing mergers and acquisitions, expanding market share, and developing new strategies to cater to evolving consumer needs and preferences. The forecast period (2025-2033) will witness significant consolidation among players and a further increase in digitalization across the industry.

Global Prescription Drugs market size 2021 was recorded $939.895 Billion whereas by the end of 2025 it will reach $1156 Billion. According to the author, by 2033 Prescription Drugs market size will become $1748.7. Prescription Drugs market will be growing at a CAGR of 5.31% during 2025 to 2033.

Discover the booming e-prescription market, projected to reach $15 billion by 2033. Explore market trends, regional insights, and key players shaping this digital healthcare revolution. Learn about the drivers, restraints and future of e-prescribing.

The Finland pharmaceutical market, exhibiting a Compound Annual Growth Rate (CAGR) of 3.90% from 2019 to 2024, presents a dynamic landscape shaped by several key factors. The market's growth is driven by an aging population leading to increased demand for chronic disease management medications, rising healthcare expenditure, and growing adoption of innovative therapies. Specific therapeutic areas like cardiovascular, oncology, and diabetes medications are expected to experience above-average growth fueled by an increase in prevalent conditions. While the market benefits from a robust healthcare infrastructure and high per capita healthcare spending, challenges exist such as stringent regulatory approvals and pricing pressures which could moderate expansion. The market is segmented by ATC/Therapeutic Class (covering areas like alimentary tract and metabolism, cardiovascular systems, and anti-infectives) and prescription type (prescription and over-the-counter drugs). Key players like AbbVie, AstraZeneca, Bayer, and others compete based on innovation, pricing strategies, and market access. The forecast period (2025-2033) anticipates continued growth, though at a potentially slightly adjusted CAGR, considering factors like generic drug competition and the ongoing evolution of healthcare policies. Growth will likely be influenced by government initiatives aimed at improving healthcare affordability and access. Considering the provided CAGR of 3.90% from 2019-2024, and assuming a slight moderation due to market maturity and potential regulatory changes, we can project a sustained, albeit slightly reduced, growth rate for the forecast period. Given the lack of specific market size data for 2024, a reasonable estimate based on industry benchmarks and the CAGR would provide a basis for projecting future values. A conservative assumption of a slightly lower CAGR during the forecast period (2025-2033) (e.g., 3.5%) would allow for modeling a realistic market trajectory. The market is segmented across various therapeutic areas, prescription types, and company participation, each influencing the overall growth dynamics. Furthermore, external factors such as economic conditions and global pharmaceutical trends will continue to play a significant role in shaping the Finnish pharmaceutical market’s future. Recent developments include: August 2023: Finland granted EUR 10 million to Orion in funding and EUR 20 million for the development of a pharmaceutical research ecosystem in Finland to reduce the time taken by pharmaceutical R&D to develop drugs., July 2023: Biovian Oy, a contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, invested EUR 50 million to expand its drug manufacturing facility in Turku, Finland. The new facility supports the development, manufacturing, and testing of advanced therapy medicinal products (ATMP) such as adenoviral and adeno-associated viral (AAV) therapies.. Key drivers for this market are: Significant research and development programs, Rising Incidence of Chronic Disease. Potential restraints include: Significant research and development programs, Rising Incidence of Chronic Disease. Notable trends are: Prescription Drugs Segment is Expected to Hold Significant Share Over the Forecast Period.

The pharmaceutical eCommerce market value is estimated to be US$ 75,527.4 million in 2024. The market is predicted to grow at a CAGR of 14.4% during the forecast period. The market valuation is estimated to reach US$ 290,824.8 million by 2034.

Report Attribute	Details
Pharmaceutical eCommerce Market Size (2024)	US$ 75,527.4 million
Anticipated Market Value (2034)	US$ 290,824.8 million
Projected Growth Rate (2024 to 2034)	14.4% CAGR

Historical Analysis of the Pharmaceutical eCommerce Market Vs Demand Outlook

Attributes	Details
Pharmaceutical eCommerce Market Value (2019)	US$ 54,772.1 million
Historical Market Revenue (2023)	US$ 73,315.6 million
Historical CAGR (2019 to 2023)	7.6%

Country-wise Insights

Countries	CAGR (2024 to 2034)
United States	7%
Germany	8%
United Kingdom	8.7%
India	20.7%
China	16%

Category-wise Insights

Attributes	Details
Top Product Type	Over-the-counter Product
Market Share in 2024	63.7%

Attributes	Details
Top End User	Consumer or Individuals
Market Share in 2024	29.8%

Pharmaceutical eCommerce Market Report Scope

Attribute	Details
Estimated Market Size (2024)	US$ 75,527.4 million
Projected Market Size (2034)	US$ 290,824.8 million
Anticipated Growth Rate (2024 to 2034)	14.4%
Forecast Period	2024 to 2034
Historical Data Available for	2019 to 2023
Market Analysis	US$ million or billion for Value and Units for Volume
Key Regions Covered	North America, Latin America, Europe, Middle East & Africa (MEA), East Asia, South Asia and Oceania
Key Segments Covered	By Product Type, By End Use Verticals, and By Region
Key Companies Profiled	Netmeds Marketplace Ltd. EasyMedico Medlife Amazon. Inc Apotek The Kroger Co. Walgreen Co. Giant Eagle, Inc. Walmart Express Scripts CVS Health Optum, Inc. L Rowland & Co (Retail) Ltd Zur Rose Group AG McKesson Corporation SHOP-APOTHEKE EUROPE N.V. UK Meds Direct Ltd. Walgreens Boots Alliance, Inc. DocMorris
Report Coverage	Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives
Customization & Pricing	Available upon Request